Coagulation factor XII protease domain crystal structure

Journal of Thrombosis and Haemostasis

Volumn 13, Issue 4, 2015, Pages 580-591

  Pathak, M ^a   Wilmann, P ^a   Awford, J ^a   Li, C ^a   Hamad, B K ^a   Fischer, P M ^a   Dreveny, I ^a   Dekker, L V ^a   Emsley, J ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Active site; Catalytic domain; Factor XII; Plasma prokallikrein; Tertiary protein structure; Zymogens

Indexed keywords

BLOOD CLOTTING FACTOR 12; ENZYME PRECURSOR; PLASMA KALLIKREIN; BLOOD CLOTTING FACTOR 12A; KALLIKREIN; PROTEIN BINDING; RECOMBINANT PROTEIN;

AMINO ACID SEQUENCE; ARTICLE; BLOOD CLOTTING; CRYSTAL STRUCTURE; CRYSTALLIZATION; ENZYME ACTIVATION; ENZYME ACTIVE SITE; HEAVY CHAIN; HUMAN; LIGHT CHAIN; MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN PURIFICATION; RESTRICTION SITE; CHEMISTRY; ENZYME SPECIFICITY; GENETICS; KINETICS; METABOLISM; MOLECULAR MODEL; MUTATION; PROTEIN TERTIARY STRUCTURE; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

BLOOD COAGULATION; CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; ENZYME ACTIVATION; ENZYME PRECURSORS; FACTOR XII; FACTOR XIIA; HUMANS; KALLIKREINS; KINETICS; MODELS, MOLECULAR; MUTATION; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EID: 84926123023     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12849     Document Type: Article

References (31)

1. Colman RW, Schmaier AH. Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood 1997; 90: 3819-43.
2. Kannemeier C, Shibamiya A, Nakazawa F, Trusheim H, Ruppert C, Markart P, Song Y, Tzima E, Kennerknecht E, Niepmann M, von Bruehl ML, Sedding D, Massberg S, Gunther A, Engelmann B, Preissner KT. Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc Natl Acad Sci USA 2007; 104: 6388-93.
3. Wilner GD, Nossel HL, LeRoy EC. Activation of Hageman factor by collagen. J Clin Invest 1968; 47: 2608-15.
4. Oehmcke S, Morgelin M, Herwald H. Activation of the human contact system on neutrophil extracellular traps. J Innate Immun 2009; 1: 225-30.
5. Houlihan LM, Davies G, Tenesa A, Harris SE, Luciano M, Gow AJ, McGhee KA, Liewald DC, Porteous DJ, Starr JM, Lowe GD, Visscher PM, Deary IJ. Common variants of large effect in F12, KNG1, and HRG are associated with activated partial thromboplastin time. Am J Hum Genet 2010; 86: 626-31.
6. Kleinschnitz C, Stoll G, Bendszus M, Schuh K, Pauer HU, Burfeind P, Renne C, Gailani D, Nieswandt B, Renne T. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med 2006; 203: 513-18.
7. van Montfoort ML, Meijers JC. Anticoagulation beyond direct thrombin and factor Xa inhibitors: indications for targeting the intrinsic pathway? Thromb Haemost 2013; 110: 223-32.
8. Larsson M, Rayzman V, Nolte MW, Nickel KF, Bjorkqvist J, Jamsa A, Hardy MP, Fries M, Schmidbauer S, Hedenqvist P, Broome M, Pragst I, Dickneite G, Wilson MJ, Nash AD, Panousis C, Renne T. A factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk. Sci Transl Med 2014; 6: 222-17.
9. Beringer DX, Kroon-Batenburg LM. The structure of the FnI-EGF-like tandem domain of coagulation factor XII solved using SIRAS. Acta Crystallogr F Struct Biol Cryst Commun 2013; 69: 94-102.
10. Iwaki T, Castellino FJ. A single plasmid transfection that offers a significant advantage associated with puromycin selection in Drosophila Schneider S2 cells expressing heterologous proteins. Cytotechnology 2008; 57: 45-9.
11. Kabsch W. XDS. Acta Crystallogr D Biol Crystallogr 2010; 66: 125-32.
12. Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 2004; 60: 2126-32.
13. Egberg N, Overmark-Berggren I. Assay for Hageman factor (factor XII) in human plasma by means of chromogenic substrate for plasma kallikrein. Thromb Res 1983; 31: 875-80.
14. Hojima Y, Tankersley DL, Miller-Andersson M, Pierce JV, Pisano JJ. Enzymatic properties of human Hageman factor fragment with plasma prekallikrein and synthetic substrates. Thromb Res 1980; 18: 417-30.
15. Jin L, Pandey P, Babine RE, Gorga JC, Seidl KJ, Gelfand E, Weaver DT, Abdel-Meguid SS, Strickler JE. Crystal structures of the FXIa catalytic domain in complex with ecotin mutants reveal substrate-like interactions. J Biol Chem 2005; 280: 4704-12.
16. Eigenbrot C, Ganesan R, Kirchhofer D. Hepatocyte growth factor activator (HGFA): molecular structure and interactions with HGFA inhibitor-1 (HAI-1). FEBS J 2010; 277: 2215-22.
17. Renatus M, Engh RA, Stubbs MT, Huber R, Fischer S, Kohnert U, Bode W. Lysine 156 promotes the anomalous proenzyme activity of tPA: X-ray crystal structure of single-chain human tPA. EMBO J 1997; 16: 4797-805.
18. Papagrigoriou E, McEwan PA, Walsh PN, Emsley J. Crystal structure of the factor XI zymogen reveals a pathway for transactivation. Nat Struct Mol Biol 2006; 13: 557-8.
19. Bunce MW, Toso R, Camire RM. Zymogen-like factor Xa variants restore thrombin generation and effectively bypass the intrinsic pathway in vitro. Blood 2011; 117: 290-8.
20. Miyazawa K, Wang Y, Minoshima S, Shimizu N, Kitamura N. Structural organization and chromosomal localization of the human hepatocyte growth factor activator gene - phylogenetic and functional relationship with blood coagulation factor XII, urokinase, and tissue-type plasminogen activator. Eur J Biochem 1998; 258: 355-61.
21. Holm L, Rosenström P. Dali server: conservation mapping in 3D. Nucl Acids Res 2010; 38: W545-9.
22. Ganesan R, Eigenbrot C, Kirchhofer D. Structural and mechanistic insight into how antibodies inhibit serine proteases. Biochem J 2010; 430: 179-89.
23. Shia S, Stamos J, Kirchhofer D, Fan B, Wu J, Corpuz RT, Santell L, Lazarus RA, Eigenbrot C. Conformational lability in serine protease active sites: structures of hepatocyte growth factor activator (HGFA) alone and with the inhibitory domain from HGFA inhibitor-1B. J Mol Biol 2005; 346: 1335-49.
24. Pathak M, Wong SS, Dreveny I, Emsley J. Structure of plasma and tissue kallikreins. Thromb Haemost 2013; 110: 423-33.
25. Lechtenberg BC, Johnson DJ, Freund SM, Huntington JA. NMR resonance assignments of thrombin reveal the conformational and dynamic effects of ligation. Proc Natl Acad Sci USA 2010; 107: 14087-92.
26. Schweinitz A, Steinmetzer T, Banke IJ, Arlt MJ, Sturzebecher A, Schuster O, Geissler A, Giersiefen H, Zeslawska E, Jacob U, Kruger A, Sturzebecher J. Design of novel and selective inhibitors of urokinase-type plasminogen activator with improved pharmacokinetic properties for use as antimetastatic agents. J Biol Chem 2004; 279: 33613-22.
27. Bode W, Schwager P, Huber R. The transition of bovine trypsinogen to a trypsin-like state upon strong ligand binding. The refined crystal structures of the bovine trypsinogen-pancreatic trypsin inhibitor complex and of its ternary complex with Ile-Val at 1.9 A resolution. J Mol Biol 1978; 118: 99-112.
28. Schwede T, Kopp J, Guex N, Peitsch MC. SWISS-MODEL: an automated protein homology-modeling server. Nucleic Acids Res 2003; 31: 3381-5.
29. Wang D, Bode W, Huber R. Bovine chymotrypsinogen A X-ray crystal structure analysis and refinement of a new crystal form at 1.8 A resolution. J Mol Biol 1985; 185: 595-624.
30. Geng Y, Verhamme IM, Smith SB, Sun MF, Matafonov A, Cheng Q, Smith SA, Morrissey JH, Gailani D. The dimeric structure of factor XI and zymogen activation. Blood 2013; 121: 3962-9.
31. Matafonov A, Leung PY, Gailani AE, Grach SL, Puy C, Cheng Q, Sun MF, McCarty OJ, Tucker EI, Kataoka H, Renne T, Morrissey JH, Gruber A, Gailani D. Factor XII inhibition reduces thrombus formation in a primate thrombosis model. Blood 2014; 123: 1739-46.